Literature DB >> 33946842

Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis.

Hideyuki Tamai1, Jumpei Okamura1, Takashi Ohoshi2, Hisao Wakasaki3.   

Abstract

Liver-related mortality rates in patients with non-alcoholic steatohepatitis (NASH) increase with advancing liver fibrosis stage. The present study aimed to elucidate whether adding non-invasive liver fibrosis tests to a comprehensive health checkup system is useful for NASH screening. Both serum Mac-2-binding protein glycosylation isomer (M2BPGi) and point shear wave elastography (pSWE) using ultrasonography were performed for 483 health checkup subjects who consented to participate in this prospective study. Outcomes in positive subjects were surveyed 1 year later. Eighty-eight subjects (18%) showed positive results for at least one liver fibrosis test, with 63 subjects positive for pSWE, 33 subjects positive for M2BPGi, and 72 subjects showing no significant elevation of liver enzymes. The secondary consultation rate for positive subjects was 52% (46/88). However, as 15 of those 46 subjects visited a non-liver-specialist and could not undergo detailed examination, the secondary examination rate was only 35% (31/88). For the 31 subjects who received secondary examination, NASH was diagnosed in 14 subjects, other chronic liver disease (CLD) in 6 subjects, and no CLD in 11 subjects. Additional liver fibrosis tests using M2BPGi and pSWE appear useful in health checkups when screening for CLD, especially for NASH.

Entities:  

Keywords:  Mac-2-binding protein glycosylation isomer; non-alcoholic steatohepatitis; screening; shear wave

Year:  2021        PMID: 33946842     DOI: 10.3390/healthcare9050523

Source DB:  PubMed          Journal:  Healthcare (Basel)        ISSN: 2227-9032


  18 in total

Review 1.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 2.  The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis.

Authors:  Julia Nierhoff; Andrea Angelina Chávez Ortiz; Eva Herrmann; Stefan Zeuzem; Mireen Friedrich-Rust
Journal:  Eur Radiol       Date:  2013-06-26       Impact factor: 5.315

3.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  J Hepatol       Date:  2016-04-07       Impact factor: 25.083

Review 4.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

5.  Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis.

Authors:  M Friedrich-Rust; J Nierhoff; M Lupsor; I Sporea; C Fierbinteanu-Braticevici; D Strobel; H Takahashi; M Yoneda; T Suda; S Zeuzem; E Herrmann
Journal:  J Viral Hepat       Date:  2011-10-30       Impact factor: 3.728

6.  Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.

Authors:  Christophe Cassinotto; Jérome Boursier; Victor de Lédinghen; Jérome Lebigot; Bruno Lapuyade; Paul Cales; Jean-Baptiste Hiriart; Sophie Michalak; Brigitte Le Bail; Victoire Cartier; Amaury Mouries; Frédéric Oberti; Isabelle Fouchard-Hubert; Julien Vergniol; Christophe Aubé
Journal:  Hepatology       Date:  2016-01-22       Impact factor: 17.425

Review 7.  Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.

Authors:  Masato Yoneda; Kento Imajo; Hirokazu Takahashi; Yuji Ogawa; Yuichiro Eguchi; Yoshio Sumida; Masashi Yoneda; Miwa Kawanaka; Satoru Saito; Katsutoshi Tokushige; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2017-11-24       Impact factor: 7.527

Review 8.  Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Rohit Loomba; Namiki Izumi
Journal:  Ann Lab Med       Date:  2020-08-25       Impact factor: 3.464

9.  Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yuka Takahashi; Yoshie Itakura; Sakura Kirino; Kento Inada; Koji Yamashita; Shuhei Sekiguchi; Yuka Hayakawa; Leona Osawa; Mayu Higuchi; Kenta Takaura; Chiaki Maeyashiki; Shun Kaneko; Yutaka Yasui; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Rohit Loomba; Namiki Izumi
Journal:  Int J Mol Sci       Date:  2020-12-22       Impact factor: 5.923

10.  Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups.

Authors:  Eun-Hee Nah; Seon Cho; Suyoung Kim; Hye-Sun Kim; Han-Ik Cho
Journal:  J Clin Lab Anal       Date:  2020-03-29       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.